Caris Life Sciences to Highlight Research at 2025 SGO Annual Meeting on Women's Cancer
IRVING, Texas, March 11, 2025 /PRNewswire/ -- Caris Life Sciences ® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, announced today that the company and collaborators within the Caris Precision Oncology Alliance™ (Caris POA) will collectively present five studies across multiple gynecological tumor types at the Society of Gynecologic Oncology's (SGO) Annual Meeting on Women's Cancer, March 14-17, 2025, in Seattle, Washington. The findings demonstrate the power of Caris' comprehensive clinico-genomic database to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.
'Caris and our POA collaborators are proud to present five studies at this year's SGO Annual Meeting highlighting the critical role of molecular profiling and biomarkers in personalizing treatment for gynecological cancers,' said Caris EVP and Chief Medical Officer George W. Sledge, Jr., MD. 'By utilizing our comprehensive clinico-genomic database, we have improved the understanding of tumor biology and shown how specific molecular characteristics affect prognosis and treatment efficacy. This work exemplifies our dedication to advancing precision medicine and optimizing oncology treatment strategies.'
Oral Presentations
Oral Featured Poster
Genomic and Immunohistochemical Characterization of NSMP Endometrial Cancer: A Novel Approach to Estrogen Receptor Positivity
Oral Featured Poster Session II: Multiple Ways to Make an IMPACT
March 15: 4:23-4:26 PM PST
Posters
GPR171, a Prognostic Marker of Improved Survival in Cervix Cancer – A Deep South Consortium in Oncology (DSCO) Project
Poster Session | March 16, 2:00 – 3:30 PM PST
Comparison of Breast and Gastric HER2 Immunohistochemistry (IHC) Scoring Criteria in the Assessment of Endometrial Carcinoma
Poster Session | March 16, 2:00 – 3:30 PM PST
Poster and abstract summaries highlighting this research will be available onsite at Caris' booth #416. The full abstracts will be available on the Caris website following the presentation.
The Caris POA includes 96 cancer centers, academic institutions, research consortia and healthcare systems, including 47 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research. Caris and POA members work together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multimodal database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides a differentiated platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition, and we value our employees as much as we do our patients. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. To learn more, please visit CarisLifeSciences.com.
214.294.5606
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
Alcon Underscores Benefits of Its IOLs and Cataract Surgical Equipment at APACRS
AHMEDABAD, India--(BUSINESS WIRE)--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced a strong presence at the 37th Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) Annual Meeting. APACRS will be held at Mahatma Mandir Convention and Exhibition Centre (MMCEC) in Ahmedabad, India from August 21-23, 2025. The company will showcase four symposia, lead 10 medical affairs scientific exchange presentations, and offer a hands-on experience zone at booth #A1). These comprehensive activities combined with new data underscore Alcon's commitment to generating meaningful scientific evidence on the safety and efficacy of its innovations. Massimo Cerrone, Vice President, Surgical for Alcon Asia Pacific, said, 'APACRS brings together leading experts and their insights from across the region, creating an ideal environment to engage in critical topics such as the evolving needs of cataract care in the ageing population. Through a dynamic agenda, surgeons can explore Alcon's latest innovations and their value through clinical evidence, real-world insights, and peer experience across Asia-Pacific.' Key data being presented at this year's event Alcon's Vivity ® is an extensively studied Extended Depth of Focus (EDOF) intraocular lens (IOL) in special populations with different co-morbidities, supported by over 10 clinical studies involving more than 700 patients. Among these is a prospective study titled, ' To Evaluate The Visual Outcomes and Patient Satisfaction After Bilateral Vivity ® IOL Implantation in Patients with Mild Irregular Astigmatism.' Conducted by Dr. Ashvin Agarwal, analyses reinforce patient satisfaction outcomes with Vivity in this specific cohort. This will be shared as an e-poster. On the cataract equipment side, Dr. Shail Vasavada of Raghudeep Eye Hospital, will present a prospective, randomized, single masked, single-center study titled, 'Retinal Perfusion During Cataract Surgery With Varying Intraocular Pressure in Comorbid Eyes.' Data underlines the benefits of performing cataract surgery at more physiologic IOP in patients with diabetic retinopathy. (Friday, 22 August 2025, 15:20pm-15:25pm, at FP3-15, Seminar Hall 2, MMCEC) Amar Vyas, Country Head, Alcon India said, 'We are excited that India is hosting APACRS for the second time. The event is an ideal platform to showcase our breakthrough technologies like the Advanced Technology IOL portfolio and UNITY VCS/CS, and foster meaningful exchange amongst ECPs. As cataract procedures rise, it's critical that advanced technologies are both clinically proven across diverse patient populations and accessible to those who need them. We remain committed to empowering surgeons with science-backed solutions that elevate surgical precision and patient outcomes.' During the meeting, Alcon will host four symposia; interested participants can learn more and register at Alcon UNITY ® VCS Launch Symposium - Ready to explore the future of Surgical Innovation? Experience Superior Efficiency - Unity ® VCS, held exclusively for India on Thursday, 21 August 2025, 12:45pm to 13:40pm IST at Seminar Hall 2, Ground Floor. This session will mark the official introduction of UNITY VCS (Vitreoretinal Cataract System) and UNITY CS (Cataract System), Alcon's next-generation Phaco/Vit platform, to the Indian market. Alcon IOL Symposium - Stay Ahead with the Clareon ® Collection on Friday, 22 August 2025,12:30pm to 13:25pm IST at Convention Hall 2, Ground Floor. This session will cover the Clareon Collection as a comprehensive IOL portfolio, discuss optical differentiation and performance of newer EDOF IOLs, and highlight the role of digital image guidance in toric correction. Alcon Surgical Video Symposium - Experience Extraordinary Phaco & VR Surgery with the NEW UNITY ® VCS by Alcon on Saturday, 23 August 2025, 12:00pm to 12:55pm IST at Convention Hall 2, Ground Floor. Through live discussion and videos, leading surgeons will showcase their experience with UNITY VCS in cataract and vitreoretinal procedures. Alcon Global Medical Affairs symposium - Vivity IOL, A True EDOF IOL with Proven Real-World Performance on Saturday, 23 August 2025, 13:00pm to 14:00pm IST at Seminar Hall 2, Ground Floor. The session, moderated by Dr. Vaishali Vasavada, will review meaningful real-world evidence supporting the use of Vivity IOL in special populations. To reserve your seat, visit For information on Alcon's presence at APACRS 2025, including the symposia and exhibition taking place at booth #A1, please visit the company's event page. The site will be updated following the event with on-demand content, such as archives of the symposia. Join the conversation on social platforms with the hashtag #APACRS2025 #Alcon. About the AcrySof IQ Vivity IOL The Wavefront Shaping AcrySof ® IQ Vivity Extended Vision Posterior Chamber Intraocular Lens Model DFT015 (referred to as AcrySof IQ Vivity IOL) is a UV-absorbing and blue light-filtering foldable intraocular lens (IOL). This IOL, compared to a monofocal IOL, provides an extended range of vision from distance to near without increasing the incidence of visual disturbances. 1 About UNITY VCS and UNITY CS The UNITY VCS (Vitreoretinal Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) and posterior segment (i.e. vitreoretinal) ophthalmic surgery. In addition, with the optional laser this system is indicated for photocoagulation (i.e. vitreoretinal and macular pathologies), iridotomy and trabeculoplasty procedures. The UNITY CS (Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) ophthalmic surgery. 2 About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at The content of this press release is intended for use by healthcare professionals only, including Registered Medical Practitioners, hospitals, or laboratories, and its use in any publication is subject to applicable local laws and regulations. References UNITY VCS and CS User Manual 2024 [REF-27652] Connect with us on: Facebook LinkedIn
Forbes
5 days ago
- Forbes
Legendary Hacker & Investor Pablos Holman's 1000x Deep Tech Future
Pablos Holman is a hacker, writ large. The first time he spoke for one of my events, in 2010, he captured an audience member's credit card information during a break and started making a purchase on stage. He didn't complete the purchase (or share the number), but he did make his point. When I'm puzzling over a truly far-out concept or epochal challenge, Holman is one of my go-to experts. He's spent his career hacking humanity's biggest challenges with organizations like Blue Origin and Intellectual Ventures. His new book, Deep Future, is a field guide to transformative technology and paradigm-shattering thinking. Fellow Technologists: 'Aim Higher!' Holman calls himself a 'Possibilist'—the future can be better, if we decide to build it. That ethos threads the book and echoes a theme I've written about for years: technology as the art of the possible. To do this well requires reframing problems, escaping established paradigms, and doing the hard work of real invention. Deep Future draws a sharp line between 'shallow tech' and 'deep tech.' Shallow tech enhances convenience. He bluntly proposes, 'If somebody makes an iPhone app to have weed delivered to their dorm room using drones, do we really have to call that tech?' Deep tech expands human capability by orders of magnitude. Holman challenges us: stop chasing 1% gains. 'Deep Tech is about finding the breakthroughs that make it possible to do things 10x, 100x, 1,000x faster, cheaper or better.' Mosquitoes Meet Lasers If you know Pablos, you know about the mosquito-zapping laser invented at Nathan Myhrvold's Intellectual Ventures. The team took apart the malaria problem and tried something new: detect the wingbeat frequency—to distinguish it from other insects—of a female Anopheles in flight and shoot it down. 'We can, and will, eradicate malaria once and for all in our lifetimes. But not by reading the directions,' he the problem, prototype shamelessly and let physics do the heavy lifting. When the approach works—even once—you've expanded what's possible. The mosquito laser array wasn't intended to go to market. Many deep tech visions are. Read the book for dozens of compelling cases. Here are three. Deep Future relates the story of Holman's fund investing in Ladon Robotics, a company reenvisioning ocean-going shipping around autonomy and wind. Consider the economics: 'About five out of six dollars spent on a ship during its life is burned as fuel. This industry literally burns most of its operational expenditures.' Ladon's idea is deceptively simple: autonomous ships powered by wind, with sun-powered battery auxiliary propulsion for navigating harbors and periods with low winds. In other words, remove fuel from the costs. It's classic deep tech. It doesn't 'improve' shipping, it transforms it. Renewables stumble on intermittency and storage. Holman proposes to ensure the sun never sets on your solar farm. 'Put those solar panels on a rocket ship, blast them into space.' Orbital solar farms could intercept sunlight 24/7, receiving eight times as much energy as they would on the Earth's surface. The system could deliver electricity via radio waves to receiving antennas on the ground, 'even in the middle of the night or during a snowstorm.' A decade ago, this would have read like a comic book. Falling launch costs and mature RF beam-forming technologies make this increasingly feasible. Holman argues, 'All the technology to do this exists already. No breakthroughs necessary.' It's a plausible path to low-cost power—precisely the kind of paradigm flip deep tech is meant to deliver. While others have proposed such a solution, Holman's venture firm Deep Future has invested in Virtus Solis, a team endeavoring to make it happen. Some of the best solutions have been around for centuries. Consider concrete, civilization's foundation and one of our dirtiest materials. Holman highlights the work of MIT's Admir Masic, which helps explain why Ancient Rome's Pantheon still stands: lime clasts throughout Roman concrete act as self-healing reservoirs. 'When water seeps in, it activates the lime and fills the cracks. It is self-healing concrete that gets stronger with time.' Longer-lasting infrastructure with 10% - 50% lower lifecycle carbon emissions. With cement accounting for approximately 8% – 13% of global CO₂ emissions, this matters. Unlike most deep tech solutions, this one has thousands of years of proof behind it. Massive Thinking, Brutal Simplicity Holman's examples—mosquito lasers, autonomous shipping, space-based solar, self-healing concrete--exhibit how to see differently: select huge problems that matter, don't let current reality get in the way, discover opportunities the incumbents ignore. While Deep Future is about audacious thinking and enormously challenging technology, much of Holman's thinking illustrates a skill I call 'brutal simplicity.' It's an approach we can all use. Here are three questions to help you do so: The first question seeks clarity before seeking solutions. Do we really understand the problem? The second tests whether we have the right problem in mind. The third question challenges us to seek as simple--though not necessarily easy--a solution as possible. Consider one of Deep Future's examples. Problem: How can we generate clean, reliable electricity at scale? Blast solar panels into space and beam the power back to Earth. Eh, voila: Virtus Solis. Ignore The Boogeymen: Build Anyway Big ideas attract bigger anxieties. Holman devotes a chapter to our habit of telling 'boogeyman' stories about new tools—nuclear, psychedelics, AI, you name it. His advice? Research, experiment, invent—then regulate the real risks we discover. The future won't be built by the skeptics. It belongs to pragmatic optimists who make better stories true. While I wouldn't expect mosquito lasers at your next BBQ, you'll likely discover a lot of you-heard-it-here-firsts in Holman's book. Thanks to the Possibilists amongst us, some of these monstrously hard, brutally simple visions will one day become reality.
Yahoo
12-08-2025
- Yahoo
Venture capital firm Speciale Invest to back Indian startups with $69 million by 2029
(Reuters) -India's Speciale Invest will invest 6 billion rupees ($69 million) over the next four years in early-stage startups spanning across sectors including artificial intelligence and space technology, the venture capital company said on Tuesday. The investment into "deep-tech" - innovations that require significant scientific research breakthroughs - comes as Prime Minister Narendra Modi aims to make India a "self-reliant" manufacturing hub and amid shifting trade relations globally, spurred by U.S. President Donald Trump's tariff policy. Founded in 2017, Speciale Invest focusses on investing in companies that are at the "seed" and "pre-seed" level of fundraising. It has previously backed air taxi startup ePlane Company and space startup Agnikul Cosmos, which launched India's second privately-built rocket last year. As part of its third funding round, the venture capital company will invest in 18 to 20 companies through 2029, with initial ticket sizes between 70 million rupees and 100 million rupees, it said. More than half of the $69 million will be reserved for follow-on investments, with some of the targets hailing from climate technology and dual-use defence sectors, it added. ($1 = 87.6050 Indian rupees)
